test

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Conditions

Adult Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Previously Untreated Childhood Rhabdomyosarcoma | Stage IV Adult Soft Tissue Sarcoma

What is the purpose of this trial?

This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with combination chemotherapy may kill more tumor cells.



Participation Guidelines

Age:
N/A - 49 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
National Cancer Institute (NCI)
Dates:
January 2010
Last Updated:
November 20, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01055314